delete National Health (Pharmaceutical Benefits) Regulations (Amendment)
Amendment to the National Health (Pharmaceutical Benefits) Regulations governing Australia's Pharmaceutical Benefits Scheme (PBS), which subsidizes prescription medications for Australians. The instrument establishes pricing mechanisms, approval processes for listing medicines, patient co-payment structures, and compliance requirements for pharmacists and pharmaceutical sponsors.
The PBS represents government price controls and market distortion in pharmaceuticals, creating a monopsony buyer that suppresses competition, reduces innovation incentives, and layers compliance costs onto pharmacies and sponsors. While providing apparent short-term affordability, it distorts price signals, creates pharmaceutical company dependency on government listing decisions, and generates significant bureaucratic approval timelines. Australians would ultimately benefit from a liberalized pharmaceutical market where competition drives down prices naturally, rather than a centrally administered subsidy scheme that merely masks true costs through taxation.